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Background Malaria remains an endemic disease in Pakistan with an 
estimated healthcare burden of 1.6 million cases annually, with Plasmodium 
vivax accounting for 67% of reported cases. P. vivax is the most common 
species causing malaria outside of Africa, with approximately 13.8 million 
reported cases worldwide.
Method We report a series of P. vivax cases with cerebral involvement that 
presented at Aga Khan University Hospital, Karachi, Pakistan.
Results The majority of the patients presented with high-grade fever accompanied by projectile 
vomiting and abnormal behaviour, seizures, shock and unconsciousness. Seven of 801 patients 
with P. vivax monoinfection presented or developed cerebral complications. P. vivax infections 
were diagnosed based on peripheral smears and rapid diagnostic testing. 
Conclusion P. vivax infection can lead to severe complications, although not with the frequency 
of Plasmodium falciparum infection. Current cases highlight an increasing trend of cerebral 
complications caused by P. vivax.
Keywords: cerebral complications, malaria, Plasmodium vivax, seizure 
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Introduction
Malaria is a global public health issue. It is a major cause 
of death from infectious disease with more than 212 million 
clinical cases annually and an estimated 429,000 deaths 
being reported worldwide. Owing to the various measures 
implemented to reduce the spread of malaria, the incidence 
of malaria has been reduced by 41% worldwide and malaria-
related deaths have reduced nearly 62% between 2000 and 
2015. However, approximately 3.2 billion people are still at 
risk of developing malaria. In 2015, the number of conﬁ rmed 
malaria cases reported in Pakistan was 202,013.1 Overall, 
the prevalence of Plasmodium vivax compared to Plasmodium 
falciparum has increased over the past few years in Pakistan.2 
Pakistan reported 10% of the total worldwide cases of P. vivax 
in 2015, and 11% of worldwide deaths due to P. vivax. 
P. falciparum is most common in Africa, while P. vivax is more 
prevalent worldwide. In Pakistan, P. vivax contributes to 85% 
cases, while P. falciparum accounts for 15%.1 Infection with 
P. falciparum is associated with a higher complication rate 
than any other type of Plasmodium infection. Complications 
associated with P. falciparum include severe anaemia, 
respiratory distress syndrome, hypoglycaemia, acidosis and 
renal failure, as well as cerebral malaria, convulsions and 
shock.3,4 Severe anaemia and hypoglycaemia occur more 
commonly in children; while respiratory oedema, renal failure 
and jaundice are common in adults. Coma and acidosis occur 
in all age groups.4
Although highly prevalent, P. vivax has always been associated 
with increased morbidity but reduced mortality compared 
to its human malarial counterpart P. falciparum.5 However, 
recent studies from Indonesia, Papua New Guinea, Thailand, 
Brazil, India, Iran and Pakistan have shown that P.  vivax, 
either independently or in synergy with comorbidities/mixed 
plasmodia species, can cause severe or even fatal malaria 
episodes.2,6–9 Several cases of severe malaria due to P. vivax 
have been reported in past decades. Complications reported 
with monoinfection of P. vivax include acute pulmonary oedema, 
severe anaemia, coma, respiratory distress, severe jaundice, 
renal failure haemodynamic shock and thrombocytopenia.6,7,10 
Risk factors associated with severe malaria are young children 
(under 5 years), pregnancy and lack of immunity.
P. falciparum is known for severe neurological complications 
and is a known cause of cerebral malaria. The mechanism 
of cerebral malaria in P. falciparum is associated with 
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microvascular occlusion, red blood cell sequestration and 
impaired perfusion due to parasitised red blood cells. There 
is also an increase in blood–brain barrier permeability, 
oedema and a mild leukocytic response.8
Neurological complications associated with P. vivax reported 
previously include thalamic bleeds, acute disseminated 
encephalomyelitis, acute subdural haematomas, bilateral 
facial palsies and facial diplegia.9,11–15 Cerebral malaria due 
to P. vivax has been reported in children.16
We report neurological complications in patients infected with 
P. vivax in our setting. Predictive and prognostic indicators for 
the development of neurological complications in a patient 
with P. vivax infection were also observed.
Methods
A retrospective study was conducted at the Aga Khan University 
Hospital, Karachi, Pakistan, and included review of charts from 
patients with P. vivax malaria enrolled over 6 years (2009–14). 
The study subjects were patients who presented with P. vivax 
monoinfection or mixed infection of P. vivax and P. falciparum 
(mixed). Inclusion criteria for the study were adults (≥18 years) 
with microscopy-conﬁ rmed P. vivax monoinfection. Patients 
infected with P. falciparum monoinfection were excluded. 
Patients with known haematological malignancies, chronic 
liver disease or hyperspleenism due to other causes were 
also excluded. Clinical syndromes were classiﬁ ed as severe 
on the basis of the World Health Organization’s 2010 severe 
P. falciparum malaria criteria with the exclusion of parasite 
density thresholds.17
Patients were further stratified based on neurological 
complications, including seizures, altered mental status, 
coma, headaches, psychosis, agitation, prostration, focal 
deﬁ cits, loss of consciousness, loss of reﬂ exes and ocular 
complications, observed within the course of disease or on 
follow up.
The data were analysed using SPSS 22. Descriptive statistics 
were calculated. The baseline characteristics of the study 
population with haematological parameters were calculated 
as mean ± standard deviation. Categorical variable was 
computed as frequency and percentages. To compare the 
P. vivax and mixed infections among different categorical 
variables appropriate chi-squared or Fisher exact tests were 
applied. Kaplan–Meier test methods were applied by using 
proportion cumulative survival function on the basis of log-
rank test methods. p-value <0.05 was considered signiﬁ cant.
Results
Of 801 patients included in the study, 715 presented with 
P. vivax and 86 with mixed infections. Seven patients with 
P. vivax monoinfection developed neurological symptoms. One 
patient had a relapse of P. vivax and presented with mixed 
infection during the relapse. Conﬁ rmation of malaria infection 
was based on blood ﬁ lm microscopy and rapid diagnostic test 
(immunochromatographic test malaria). The mean patient age 
was 44 years, range: 19–75 years. Interestingly, the patients 
who developed neurological symptoms were male.
Patients with neurological complication had pre-existing 
comorbidities, such as hypertension, epilepsy, diabetes 
mellitus type II or cardiovascular disease, among others. 
Presenting symptoms in patients with monoinfection P. vivax, 
haematological parameters and gender associations to 
neurological complications are compared in Table 1.
We compared several presenting complaints, including 
uncontrolled movements, seizure, rash, paresis/paralysis, 
loss of consciousness, vomiting and fever in patients with 
P. vivax infection. All patients with mixed infections presented 
with mostly non-speciﬁ c symptoms, with loss of appetite 
being common in mixed malaria patients, but not in patients 
with P. vivax.
Physical examination of the patients with P. vivax 
monoinfection at the time of admission showed normal 
neurological function that deteriorated later during admission. 
MRI findings observed in P. vivax-positive patients who 
developed neurological complications were cortical infarcts, 
cerebral oedema, basilar haemorrhage and frontoparietal 
haemorrhage to ex-vacuo lateral ventricle dilation.
Mean platelet count in patients with malaria was 50.44 x 
104 platelets, with a lower count in P. vivax monoinfection 
patients. Prothrombin time was found to be signiﬁ cantly lower 
in patients with P. vivax monoinfection (11.63 ± 1.16 s) than 
with mixed infection (20.70 ± 6.08 s; p-value: 0.006).
Treatment of patients infected with P. vivax only comprised 
artemether alone (22.2%), chloroquine alone (22.2%) and 
artemether in combination with chloroquine (33.3%). The 
average hospital stay was 6.2 days (standard deviation: 
9.48 days; range: 1–30 days). The median hospital stay was 
calculated (to eliminate the one extreme value of 30 days) 
as 3 days.
All seven patients with neurological complaints survived 
without any residual symptoms. One patient died (11.1%) 
from the course of disease. Mixed malaria infection was 
associated with poorer outcomes and a higher rate of 
deterioration (Figure 1). The type of malaria or the outcome 
(alive vs dead) was not found to have any significant 
association to the duration of stay at the hospital.
Further analysis revealed no relationship between associated 
comorbidities and patient outcome, or between various 
presenting complaints and patient outcome. Although most 
patients with malaria presented with normal neurological exam, 
upgoing planters response was seen with poorer outcomes.
Discussion
Our results revealed male gender to be a predisposing 
factor for the development of neurological complications in 
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patients with P. vivax. Few cases address female patients 
developing neurological complications. The average patient 
age was 44 years. Neurological complications in P. vivax 
have been reported in the paediatric age group.16 Several 
cases reported from neighbouring India involving neurological 
complications in adults with P. vivax concur with data reported 
in this study.9,11,12,14,15
Patients with mixed infection of P. falciparum and P. vivax 
presented with symptoms non-specific for neurological 
complications, with loss of appetite being common. However, 
patients with P. vivax monoinfection presented with symptoms 
more specific for neurological involvement, including 
drowsiness, paresis, uncontrolled hand movements, loss of 
consciousness and seizures.
Patients with P. vivax monoinfection presented with normal 
neurological examinations at the time of admission but later 
developed neurological complications, such as extensor 
planter reﬂ ex (Babinski response). Previous studies have 
revealed coma to be the most signiﬁ cant prognostic factor 
in terms of patient mortality associated with severe malaria 
in P. falciparum.4 This ﬁ nding is consistent with our study in 
which drowsiness with associated upgoing planters response 
and was related to mortality.
Thrombocytopenia observed in this study was more severe 
in P. vivax monoinfection than in mixed infections. Severe 
Figure 1 Survival in patients with Plasmodium vivax and mixed 
infection that developed neurological complications. Survival 
curves were generated by applying Kaplan–Meier test method 
using proportion cumulative survival function on the basis of 
log-rank test methods
Table 1 Clinical features of patients with severe Plasmodium vivax infection from Karachi, Pakistan
Characteristic No. patients with P. vivax monoinfection
1 2 3 4 5 6 7 Descriptive statistics*
Age (year) 44 35 54 19 34 75 54 Mean ± SD: 31.0 ± 15.33
Duration of illness 
(hospital stay in days) 
4 3 2 2 1 8 4 Mean ± SD: 2.5 ± 1.19
Fever + + + + + + + Present in 7/7 (100%)
Seizures – + + – – – + Present in 3/7 (42%)
Vomiting + – – + – + – Present in 3/7 (42%)
Drowsiness – – – – + + – Present in 2/7 (28%)
Malaise + – – + – – – Present in 2/7 (28%)
Paresis – – – – + – – Present in 1/7 (14%)
Loss of consciousness – – + – – + – Present in 2/7 (28%)
Extensor planter reflex – – – – + – + Present in 2/7 (28%)
Uncontrolled hand 
movements
+ – – – – – – Present in 1/7 (14%)
Haematological parameters
Haemoglobin (gm/dl) 11.1 9.8 13.5 11 14.1 8.1 13.5 Mean ± SD: 11.5 ± 2.2
Prothrombin time (s) 12.5 13.4 10.9 10.6 10.6 12.6 11.7 Mean ± SD: 11.6 ± 1.2
Haematocrit (%) 33 28 38 31.7 41 23.5 38.2 Mean ± SD: 33 ± 6
Platelets (109/l) 30 72 96 17 17 71 17 Mean ± SD: 45 ± 33
Serum creatinine (mg/dl) 1.4 0.4 1.10 1 0.9 1.4 1.2 Mean ± SD: 1.05 ± 0.3
Malaria treatment
AT CQ, AT AT CQ AT, CQ CQ, AT CQ
 All patients were male.
*Statistics derived in SPSS software version 22.
+, present; AT, atemether oral; CQ, chloroquine; SD, standard deviation
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thrombocytopenia has been associated with P. vivax 
patients.6
Patients with P. vivax monoinfection presented with lower 
platelet counts than those with mixed infection, which 
concurs with previous studies.2 However, this ﬁ nding is 
in contrast to previous studies that indicate P. falciparum 
attenuates the intensity of P. vivax infection.18 Yet, 
prothrombin time was higher with mixed infections than 
P. vivax monoinfection.
Cortical infarcts, cerebral oedema, basilar hemorrhage, 
frontoparietal haemorrhage and ex-vacuo lateral ventricle 
dilation were seen on MRI. Previous reports have shown 
that cerebral malaria is most commonly associated with the 
paediatric age group.19 Mixed infections are associated with 
higher mortality and a higher rate of deterioration.5
Multiorgan dysfunction observed during severe malaria is 
associated with a systemic inﬂ ammatory response triggered 
by, among other factors, leukocyte adhesion to organ 
microvasculature, parasitised erythrocytes and production 
of inﬂ ammatory mediator. Multiorgan dysfunction has been 
reported in India and Brazil and found to be associated with 
poor outcomes in severe P. vivax malaria cases.20,21
P. vivax is a major contributor to the disease effects of 
malaria, including severe malaria, in a tertiary care setting in 
Karachi, Pakistan. Furthermore, P. falciparum and P. vivax have 
similar rates for several complications (pulmonary oedema, 
metabolic acidosis, abnormal bleeding, renal impairment and 
death). Severe malaria with cerebral complications due to 
P. vivax would place an additional burden on a weak healthcare 
system leading to increased morbidity and mortality.
Safety practices to avoid exposure are the primary prevention 
method. Immediate reporting of suspected exposures is 
important to initiate prompt evaluation and treatment, 
if needed. Recommended prophylaxis for P. vivax high 
endemic areas are chloroquine (two tablets weekly 155 mg) 
plus proguanil (two tablets daily 100 mg).22 Effective 
chemoprophylaxis taken correctly should reduce the risk of 
malaria by around 90%, especially if combined with sleeping 
under insecticide-treated nets. 
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